Hemolysis of patients with end stage renal disease evaluated by erythrocyte creatine

Hemolysis of patients with end stage renal disease evaluated by erythrocyte creatine - Hemolysis of end stage renal disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036418

Enrollment

Registered

2019-04-05

Start date

2019-04-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End stage renal disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who received hemodialysis and peritoneal dialysis

Exclusion criteria

Exclusion criteria: Patients with malignant tumor Patients with auto immune hemolytic anemia Patients who received transfusion within 3 months Patients with myelodysplastic syndromes

Design outcomes

Primary

Measure	Time frame
Severity of hemolysis between hemodialysis and peritoneal dialysis	—

Secondary

Measure	Time frame
Comparison of long-term prognosis with all-cause death between end stage renal disease participants with and without hemolysis	—

Countries

Japan

Contacts

Public ContactShinobu Bandou

Kansai Medical University Medical Center Department of Cardiology

bandoshi@takii.kmu.ac.jp+81-6-6992-1001

Outcome results